Skip to Main Content

Paper Details

A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity.
Nat Commun
32
2022
CAR, CAR T, CAR T cell, Chimeric, Chimeric antigen receptor, IL-7, T cell, hematologic malignancies, human, human CAR T cells, hyFc, hybrid Fc, interleukin-7, mouse, murine, murine CAR T cells, patients, pro-lymphoid growth factor, recombinant human interleukin-7, rhIL-7, tumor, tumor cell
Author NameAffiliation
Reyka G JayasingheWashington University in St. Louis
Reyka G JayasingheWashington University in St. Louis
John F DiPersioWashington University in St. Louis
  • 1 - 3

Datasets

Release 1.2